Dear Sirs,

We report four cases of severe COVID-19 in male patients aged 50--70 with the combination of central and peripheral nervous system disorders occurring unexpectedly late after the first symptoms. Patients had comorbidities and were admitted for acute respiratory distress syndrome due to a proven SARS-CoV-2 infection. All required mechanical ventilation, among whom one needed an extracorporeal membrane oxygenation support.

Several acute neurological syndromes have been associated with SARS-CoV-2 infection, including anosmia and ageusia \[[@CR1], [@CR2]\], meningoencephalitis \[[@CR3], [@CR4]\], acute hemorrhagic necrotizing encephalopathy \[[@CR5]\], axonal or demyelinating polyradiculoneuropathy \[[@CR6]--[@CR8]\], polyneuritis cranialis \[[@CR8]\]. Like in most of the viral infections that involve nervous system, these manifestations occurred within the first ten days after infectious symptoms. Further away from the onset of the disease, when sedation and neuromuscular blocker were withheld, 67% of the patients with severe COVID-19 develop encephalopathy including prominent agitation, confusion and corticospinal tract signs \[[@CR9]\].

In our cases neurological manifestations were detected after mechanical ventilation weaning and extubation (Fig. [1](#Fig1){ref-type="fig"}). They consisted of miscellaneous symptoms such as confusion, cognitive dysfunction (memory deficit, frontal syndrome), psychiatric disorders (paranoid delusion, hallucinations), weakness, pyramidal signs, dysautonomia, swallowing dysfunction, vertical supranuclear eye palsy, upper limbs myoclonus, fasciculation and focal muscle atrophy (Table [1](#Tab1){ref-type="table"}). To note, before admission to intensive care unit, patients had no neurological symptom, except for anosmia or ageusia in two of them. One patient had a small acute sub-cortical ischemic stroke on brain MRI. Cerebrospinal fluid (CSF) analysis showed a normal cell count and a moderate increase of protein level in the up to 80 mg/L in two cases. RT-PCR and IgM for SARS-CoV-2 in the CSF were negative in all patients. On EEG, non-rhythmic frontal slow waves were observed in two patients. Three patients had electrophysiological features of acute motor demyelinating polyradiculoneuropathy with delayed distal latencies and F-waves, slowed conduction velocities and conduction blocks (Supplementary Table). The remaining patient had lower motor neuron features in both the upper and lower limbs. Two patients had an additional decrease of sensorimotor potential amplitude compatible with a critical illness neuropathy. Swallowing and eye movement improved within the first week. Given the persistent muscle weakness and electromyographic features suggesting a post-infectious mechanism, an immunoglobulin therapy was introduced for 5 days. Psychiatric symptoms, cognitive impairment and dysautonomia improved thereafter, but myoclonus and motor weakness of the upper limbs persisted 3 weeks after discharge. Three patients required prolonged rehabilitation in a specialized center.Fig. 1Timelines showing general and neurological symptoms onset, timing of hospital admission and discharge, timing of ICU admission and discharge, and paraclinical examinations and treatments. *EEG,*electroencephalogram; *EMG* electromyogram; *ICU* intensive care unit; *IVIg* intravenous immunoglobulin; *MRI* magnetic resonance imagery. P1: Patient 1 (M, 62 y.o), P2: Patient 2 (M, 72 y.o), P3: Patient 3 (M, 50 y.o), P4: Patient 4 (M, 66 y.o). For P2, cerebral and spinal MRI were performed at two different dates (days 49 and 62, respectively)Table 1Characteristics and management of severe COVID-19 patients presenting with mixed central and peripheral neurological manifestationsID age sexComorbiditiesDelay between inaugural symptoms and admission to:Inaugural symptomsNeurologic features at evaluation^a^MRIEEGEMG (main features)SARS-CoV-2 RT-PCR Serology^a^CSF^b^ WCC/Protein mg/L SARS-CoV-2 testsSeverity of ARDS^c^ and medical care1, 62, MHypertension, diabetes mellitusHospital: 10 days, ICU: 12 daysFever, cough, ageusia, dyspneaConfusion, dysexecutive syndrome, memory deficit, swallowing disorders, left facial palsy, right UL weakness (2/5) with bilateral atrophy of the first palmar interosseous, left UL and LL strength 4/5, ataxia, postural and action myoclonus, lower limb areflexia, upper limb hyperreflexia, dysautonomia^d^, GSC 15, mRS 5 (^a^day 21)Recent ischemic stroke in right middle cerebral artery territory (Brain MRI) Normal spinal cord MRIGlobal slowing (5--6 Hz) Bilateral and frontal, disphasic, non-periodic slow activity (2 Hz)Demyelinating asymmetric motor polyradiculo neuropathy and moderate axonal sensorimotor neuropathy of the four limbsPositive RT-PCR in nasopharyngeal swab, + IgM, + IgG in plasma (^a^day 13)0 / 45 negative RT-PCR,- IgM, + IgG, No intrathecal synthesisMild ARDS^e^ Hydroxychloroquine sulfate 600 mg Azithromycin 250 mg, ICU, V, no PP, IVIg 0.4 g/kg, Rehabilitation center after 36 days, mRS 22, 72, MHypertension, Diabetes mellitus, Obesity, (BMI = 31.5), Urothelial carcinoma in remissionHospital:15 days, ICU: 17 daysFever, cough, dyspneaConfusion, paranoid delusion, visual and auditory hallucinations, frontal syndrome, memory deficit, swallowing disorders, tetraparesis (UL and LL strength 2/5), ataxia, UL rest, postural and action myoclonus, slowing of eye movement saccades, four limbs hyperreflexia and neurogenic pain, dysautonomia^d^, GSC 14, mRS 5 (^a^day 44)Normal brain and spinal cord MRIGlobal slowing (5--6 Hz)Demyelinating motor polyradiculoneuropathy and moderate to severe axonal sensorimotor neuropathy of the four limbsPositive RT-PCR in nasopharyngeal swab, + IgM,---IgG in plasma, (^a^day 18)0 / 74, negative RT-PCR,---IgM, + IgG, No intrathecal synthesisMild to moderate ARDS^e^ Hydroxychloroquine sulfate 600 mg, Azithromycin 250 mgQT prolongation, Pregabalin 300 mg per day, ICU, V, no PP IVIg 0.4 g/kg, Rehabilitation center after 50 days, mRS 43, 50, MDiabetes mellitusHospital: 18 days, ICU:20 daysCough, dyspneaConfusion, paranoid delusion, frontal syndrome, memory deficit, swallowing disorders, tetraparesis, (UL strength 2/5 and LL strength 3/5), bilateral atrophy of the first palmar interosseous, ataxia, UL rest, postural and action myoclonus, slowing of eye movement saccades, four limbs hyperreflexia, bilateral ankle clonus, dysautonomia^d^, GSC 14, mRS 5 (^a^day 54)Normal brain and spinal cord MRIPosterior and metric global slowing (6 Hz) bilateral frontal paroxysmal slow, delta wavesLower motor neuron involvement with denervation of the four limbs, normal motor evoked potential amplitudePositive RT-PCR in nasopharyngeal swab + IgM, + IgG in plasma (^a^day 19)5 / 81 negative RT-PCR---IgM, + IgG, No intrathecal synthesisModerate to severe ARDS^e,^ Hydroxychloroquine sulfate 600 mg, Azithromycin 250 mgMethylprednisolone 1 g, ICU, ECMO, V, PP (× 1), IVIg 0.4 g/kg, Rehabilitation center after 76 days, mRS 44, 66, MObstructive sleep apnea syndromeHospital: 10 days, ICU: 12 daysCough, Dyspnea, Anosmia, DiarrheaConfusion, paranoid delusion, visual hallucinations, frontal syndrome, memory deficit, tetraparesis (UL and LL strength 3/5), ataxia, UL postural and action myoclonus, UL hyperreflexia, LL areflexia, dysautonomia^d^, GSC 15, mRS 4 (^a^day 42)Normal brain and spinal cord MRINormalDemyelinating motor polyradiculo neuropathy of the four limbsPositive RT-PCR in nasopharyngeal swab,---IgM, + IgG in plasma (^a^day 10)1 / 22, negative RT-PCR,- IgM, + IgG, No intrathecal synthesisMild to severe ARDS^e,^ Hydroxychloroquine sulfate 600 mg, Azithromycin 250 mg (day 11--18) Methylprednisolone 1 g (day 20 to 26) ICU, V, PP (× 6) IVIg 0.4 g/kg, Discharged at home after 40 daysmRS 2*BMI* body mass index; *CSF* cerebrospinal fluid; *ECMO* extracorporeal membrane oxygenation; *EEG* electroencephalogram; *EMG* electromyogram; *GSC* Glasgow scale; *ICU* intensive care unit; *IgM* immunoglobulin M; *IgG* immunoglobulin G; *IVIg* intravenous immunoglobulin; *LL* lower limb; *UL* upper limb; *MRI* magnetic resonance imaging; mRS, modified Rankin Scale; *NA* not applicable; *PP* prone position; *RT-PCR* real-time polymerase chain reaction; *V* mechanical ventilation; *WCC* white cell count (µL)^a^Time after inaugural symptoms^b^Cerebrospinal fluid analysis was performed at the time of neurological examination^c^Severe Acute Respiratory Distress Syndrome (ARDS): PaO2/FiO2 \< 100; moderate *ARDS*: PaO2/FiO2 \< 200; mild, *ARDS*: PaO2/FiO2 \< 300; *PaO2/FiO2* ratio was calculated using the arterial Pressure of oxygen (PaO2) and the fraction of inspired oxygen (FiO2) in mechanical ventilated patients^d^Dysautonomia: orthostatic hypotension, constipation^e^Patient 1 (PaO2/FiO2): day 1: 208, day 2: 280, day 3: 240, day 7: 218; Patient 2 (PaO2/FiO2): day 1: 224, day 2: 220, day 3: 204, day 7: 174; Patient 3 (PaO2/FiO2): day 1: 140, day 2: 203, day 3: 78, day 7: 44; Patient 4 (PaO2/FiO2): day 1: 75, day 2: 234, day 3: 162, day 7: 69mRS was defined as: **0**: No symptoms at all; **1**:No significant disability despite symptoms; able to carry out all usual duties and activities; **2**:Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; **3**:Moderate disability; requiring some help, but able to walk without assistance; **4**:Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; **5**:Severe disability; bedridden, incontinent and requiring constant nursing care and attention

We describe here delayed mixed central and peripheral disorders as a complication of severe COVID-19. It combines acute encephalopathy and motor demyelinating polyradiculoneuropathy or diffuse lower motor neuron involvement. Persistent cognitive and motor deficit might result from a critical illness, but neurological features differ from critical illness-related encephalopathy and neuropathy. Critical illness-related neuropathy is characterized by a bilateral, symmetric, axonal sensorimotor polyneuropathy resulting in an areflexic tetraplegia, without dysautonomia or cranial nerves palsy. In our patients, clinical and neurophysiological features of peripheral nervous system involvement could partly reflect critical illness neuropathy but most of them are not expected in this context and are thus more likely linked to COVID-19. Abnormal eye movement, swallowing dysfunction and action myoclonus are unusual in critical illness-related encephalopathy and might rather result from COVID19-related brainstem dysfunction in our patients.

Our study suggests a wider spectrum than previously reported of neurological manifestations associated with COVID-19 and further suggests that patients with severe forms of COVID-19 should be systematically screened for neurological complications.
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